| YBioC4001 | Haemophilia | Vial | For local manufacturing, technology transfer ongoing | Direct import product marketed since 2022 | Marketed |
| YBioA4002 | Cancer | Vial | 3 validation batches manufactured (API and F&F) | Dossier will be submitted Q2/2025 | 2026 |
| YBioF0001 | Cancer | Vial | 3 validation batches manufactured (F&F) | Registration submitted | 2025 |
| YBioC4002 | Rheumatology | PFS | TBD | Registration submitted | 2025 |
| YBioC4003 | Cancer, Heamatology | Vial | TBD | Registration submitted | 2025 |
| YBioF0002 | Cancer | Vial | 3 validation batches manufactured (F&F) | Dossier will be submitted Q4/2025 | 2026 |
| YBioF0003 | Osteoporosis | Pen | 3 validation batches manufactured (F&F) | Dossier will be submitted Q2/2025 | 2026 |
| YBioA4001 | Gynecology | Pen and Vial | 3 validation batches manufactured (API and F&F) | Dossier will be submitted Q1/2027 | 2028 |
| YBioA4003 | Rare Blood Diseases | Vial | Cell line and process development (API and F&F) | Dossier will be submitted 2028 | 2029 |
